Barely Significant
← all excerpts

The Clinical Impact of Capmatinib in the Treatment of Advanced Non-Small Cell Lung Cancer with MET Exon 14 Skipping Mutation or Gene Amplification.

Cancer Res Treat · 2021 · PMC8524022 · PMID 33540494

Europe PMCDOI
1
hedged sentence
0.1230
closest p · 2.5× alpha
0.1230
boldest claim

The sentences

showed a trendp=0.123not close (p > 0.1)
Among all capmatinib-untreated patients (n=59), group A showed a trend towards worse OS to group B (median OS, 7.5 months vs. 11.3 months; p=0.123).

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.